Freelance Pharmaceutical And Biotech Writer
Nick Paul Taylor is a Freelance Pharmaceutical and Biotech Writer. He specializes in various aspects of medicine and healthcare, focusing on pharmaceuticals, healthcare technology, medical specialties, and medical technology. His work has been featured in prominent publications such as Healthcare Dive, BioPharma Dive, and Yahoo Finance, among others.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Nick Paul Taylor's articles are focused on the healthcare and pharmaceutical industry, particularly highlighting data-driven content. His coverage centers around medical technology, pharmaceutical companies, clinical trials, drug development, and biotechnology.
Given his focus on citing data and press releases, Nick is likely to be interested in pitches that provide newsworthy statistics or insights from credible sources within the healthcare and pharmaceutical sectors. He may also respond well to pitches related to government announcements impacting these industries.
As he does not have a specific geographic focus mentioned but covers global pharmaceutical news extensively, consider providing international perspectives or insights when reaching out for potential collaboration.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Johnson & Johnson expects U.S. physicians to perform the first procedures with the device this summer as it starts a phased commercial rollout.
By: Nick, Paul Taylor
Biopharma companies won't fully capture the benefits of AI unless they reorganize their R&D units, according to McKinsey.
By: Nick, Paul Taylor
Regulators on both sides of the Atlantic are pushing for the withdrawal of the rare disease treatment that accounted for just 1% of Amgen's 2025 revenue. Nevertheless, Amgen continues to defend the medicine, which was acquired in the $3.7 billion buyout of ChemoCentryx.
By: Nick, Paul Taylor
Real Chemistry has launched artificial intelligence tools for healthcare commercialization, continuing its embrace of technology tipped to transform biopharma marketing.
By: Nick, Paul Taylor
Through the proposal, the FDA could clear barriers to distributed manufacturing approaches intended to enhance emergency preparedness and supply chain resilience.
Summit Therapeutics has cleared out an asset from its pre-ivonescimab history, offloading the antibiotic candidate ridinilazole to the OpenAI-backed startup Biossil for $500,000 upfront.
By: Nick, Paul Taylor
Chai Discovery has continued its whirlwind emergence, closing its third financing round in less than a year to bring its total funding haul above $600 million.
HistoSonics’ phased commercial rollout of the Edison system will initially target centers specializing in liver tumor treatment.
Attovia Therapeutics has filed for an IPO to secure funding for assets including a potential challenger to Sanofi and Regeneron's Dupixent and Galderma's Nemluvio.
By: Nick, Paul Taylor
An inspection of a facility making Elevar's rivoceranib uncovered deficiencies, leading the FDA to reject a combination therapy that includes the drug. The rebuff is the third strike for the partners after the agency issued manufacturing-related denials for the other drug in the combo.
